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Malaria situation 
Malaria is one of the most important causes of 
morbidity and mortality in tropical countries. The 
World Health Organization considers the world-
wide annual incidence of acute malaria to be 270 
million infections and 110 million clinical cases 
[28]. The number of deaths is estimated at 1-2 
million per annum. Contributing to this death rate 
is the particularly high fatality rate of approxi-
mately 2% in multiresistant Plasmodium jalcipar-
um infections [21]. 
Since the description of the first chloroquine-
resistant P. jalciparum strains in Thailand in 1959 
and Columbia in 1960 [16] the problem of resis-
tance has expanded to more than 50 countries [13]. 
Furthermore, resistance against the majority of 
currently available antimalarial agents has devel-
oped as well, especially in Africa and Southeast 
Asia. A 1989 study in Thailand reported that the 
efficacy of chloroquine was almost 0% and that 
of sulfadoxine/pyrimethamine less than 10%. Qui-
ni ne as monotherapy had an efficacy of 60% and 
mefloquine one of not more than 80% [6] (Fig. 1). 
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Fig. 1. Increase in resistance to various antimalarials in Thai-
land (from [6]) 
In 1986 the established combination of mefloquine 
with sulfadoxine and pyrimethamine, which had 
been introduced to delay the evolution of resis-
tance to mefloquine, was effective in 98 % of all 
P. jalciparum infections. However, in a prospective 
study conducted in the same area in 1990, the effi-
cacy had al ready dropped to 71 % [14]. This in-
crease in resistance to mefloquine mayaiso in-
crease the resistance to quinine because of structur-
al similarities [24]. Due to this continuously wor-
sening malaria situation there is an urgent need 
for new and, especially, structurally different anti-
malarial agents. 
Halofantrine 
The Walter Reed Army Institute for Research has 
tested more than 300000 substances within the 
scope of its antimalarial drug development pro-
gram; of these, 9000 have shown potential antima-
larial activity. Among the substances entering fur-
ther development was halofantrine, which had 
been described as (a potential) antimalarial as early 
as the Second World War [27]. Halofantrine is an 
amino alcohol and belongs to the class of 9-phen-
antrenmethanols, which have not yet been used 
in the treatment of malaria. The risk of cross-resis-
tance to other antimalarials, which in general are 
aminoquinolones, seems to be minor as the struc-
ture of halofantrine is basically different (Fig. 2). 
Halofantrine is a blood schizontocide affecting 
only trophozoites and schizonts in the red blood 
cells. As with all other blood schizontocides, halo-
fan trine is ineffective against the liver forms of P. 
vivax and P. ovale. Thus, additional treatment with 
a tissue schizontocide such as primaquine is indi-
cated in these infections. 
The mechanism of action of halofantrine is not 
yet completely understood. The substance seems 
to bind to ferriprotoporphyrin IX in red blood cells 
affected by plasmodia [3]. Further modes of action 
which have not yet been observed with other anti-
malarials may include inhibition of the proton-
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Fig. 2. Structure of various antimalarials 
pump at the parasite-erythrocyte contact spot [25] 
as well as an effect on mitochondria and hemato-
zoin vesic1es of the Plasmodium [17]. 
The antimalarial efficacy of halo fan trine has 
been demonstrated both in vivo in various rodents 
and primate species and in vitro. The in vitro tests 
were performed by determinating the uptake of 
radioactively labeled hypoxanthine in the erythro-
cyte stages of chloroquine-sensitive and chloro-
quine-resistant P. jalciparum strains. The mean in-
hibitory concentration for halofantrine was 2.5 
and 3.2 ng/ml, respectively, compared to 6.7 and 
7.8 ng/ml for mefloquine. For both substances 
cross-resistance to chloroquine can thus be ex-
c1uded c1inically [20]. The in vitro efficacy of halo-
fan trine has also been verified through c1inical 
isolates of P. jalciparum cases from Asia and Afri-
ca [15, 26] (Table 1). 
In vitro comparisons of the mean inhibitory 
concentrations of halofantrine and mefloquine in 
235 c1inical P. jalciparum isolates from various en-
demie areas did not indicate cross-resistance be-
tween the two substances. However, resistance may 
be induced by incubating P. jalciparum isolates in 
increasing mefloquine concentrations. The mean 
inhibitory concentration of mefloquine thereby in-
creases five fold, whereas the increase with halo-
fan trine is only two fold [20]. 
Halofantrine is only poorly and incompletely 
absorbed after oral administration. Although great 
inter- and intraindividual differences in kinetics are 
evident; the maximum plasma concentration is 
consistently reached by about 6 h [5]. Above a sin-
gle dose of 500-750 mg absorption of the sub-
stance does not increase further. Because of this 
ceiling effect and the great variability in absorption 
Table 1. In vitro antimalarial activity of drugs against P. falä-
parum isolates from naturally acquired malaria infections in 
West Africa and Thailand 
Mean ICso (ng/ml) 
Country Chloro- Meflo- Quinine Halofan-
quine quine trine 
Sierra Leone 4.73 24.50 53.60 3.90 
Sierra Leone 6.39 18.71 40.09 3.60 
Nigeria 6.91 15.03 40.33 1-26 
Nigeria 7.20 11.83 40.80 0.90 
Nigeria 8.41 17.06 77.99 4.70 
Nigeria 4.73 32.39 91.15 2.40 
Sudan 6.39 1.57 10.65 0.33 
Indochina 6.91 4.30 90.75 0.45 
Thailand a 7.20 5.33 165.61 0.68 
a All cases 
halo fan trine cannot be used as single dose. During 
the dose-finding studies a dosage regime of 3 x 
500 mg halofantrine at 6-h intervals was shown 
to be most effective. However, absorption and 
pharmacokinetics of halofantrine can be improved 
with high-fat meals, with the Cmax being up to six 
fold [12]. Bioequivalence data of different formula-
tions have revealed that absorption of the suspen-
sion is 20% lower than that with tablets and cap-
sules. Again, inter- and intraindividual variations 
must be taken into account. 
The main metabolite of halofantrine is an N-
desbutylhalofantrine, which also has schizontoci-
dal activity. The elimination half-life of halo fan-
trine is 1-2 days, and that for the equally effective 
metabolite 3-5 days. Elimination kinetics and 
especially duration of subtherapeutic substance 
levels are a major determinant in the development 
of resistance against antimalarials. Because of the 
substantially shorter elimination and half-life dura-
tion of subtherapeutic levels of halo fan trine com-
pared to chloroquine and mefloquine the problem 
of resistance to halofantrine should be significantly 
less [1] (Fig. 3). Halofantrine is not suitable for 
prophylactic use because of its pharmacokinetics, 
which, again, should delay the development of re-
sistance. 
Halofantrine is neither mutagenic nor terato-
genie. Because of its embryotoxicity, however, ha-
lofantrine is justified during pregnancy only for 
vital indications and in the absence of an alterna-
tive compound. Halofantrine had no negative im-
pact on the major organ systems in the dose ranges 
tested. Unlike most other antimalarials, halofan-
trine does especially not interfere with the mecha-
ni sm of insulin secretion, with the risk of hypogly-
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Fig. 3. Pharmacokinetics ofmefloquine and halofantrine: dura-
tion of subtherapeutic levels. Subtherapeutical Level Halofan-
trine: Day 13-28; Subtherapeutical Level Mefloquine: Day 57-
193. - Halof.+Metab. (Crnax =6.4; 0.7) (TO.5=38 h; 103 h); 
--- Mefloquine (Crnax = 6.0) (TO.5 = 21 d); -- Detection Limit 
cemic episodes particularly deleterious in cerebral 
malaria [18]. 
Studies on halofantrine 
Up to now, more than 2000 patients with acute 
malaria have been treated in c1inical studies with 
halofantrine, 1474 of them according to the opti-
mal dosage scheme of 3 x 500 mg halofantrine at 
6-h intervals. Approximately 20% of the patients 
were children below the age of 5 years. These stud-
ies were conducted between 1985 and 1990 mainly 
in West and East Africa, Southeast Asia, and the 
Pacific area, thus in areas with high chloroquine 
and multidrug resistance [9]. 
Of the 1474 patients 1315 were infected with 
P. jalciparum, 122 with P. vivax, and the rest with 
P. ovale, P. malariae or mixed infections. Inc1uded 
in the studies were patients with a parasite count 
between 1000 nd 250000 parasitesjcm2 . Exc1usion 
criteria were severe or complicated malaria such 
as cerebral malaria, acute renal failure, acute liver 
failure, protracted vomiting, pregnancy, and pre-
treatment with another antimalarial within the pre-
vious 14 days. For each study local ethical review 
committee approval had been obtained; patients 
gave written or oral, witnessed, informed consent 
prior to study entry. Parasitemia was c1eared with-
in 7 days in all but eight patients (0.5%). The me an 
fever c1earance time was 50.2 h for P. jalciparum 
and 49.6 h for P. vivax infections. The mean para-
site c1earance time was 57.9 hand 57.3 h, respec-
tively. 
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During the observation period of 28 days, the 
recrudescence of P. jalciparum parasitemia oc-
curred in 77 patients (6%), mainly nonimmune 
persons or infants below the age of 2 years. How-
ever, it cannot be exc1uded that some of these pa-
rasitemias were in fact new infections, as perma-
nent isolation of the patients over 28 days was 
practically impossible. In P. vivax malaria six re-
crudescences occurred (5.4%). Thus, the overall 
efficacy of halojantrine for treatment of acute 
malaria can be considered at least 94%, even in 
areas with unfavorable resistance and high trans-
mission rate. 
Halofantrine was in general well tolerated. 
Fewer than 5% of the patients experienced mild 
and transitory diarrhea or irritation of the intesti-
nal tract. Rare events inc1uded cough itching, and 
headache. Laboratory abnormalities such as ane-
mia, thrombocytopenia, and increased trans amin-
ases at study entry were considered disease - but 
not drug - related by the investigators and normal-
ized in par~llel to the improvement of the c1inical 
condition. Central nervous symptoms, seizures, or 
psychotic episodes were not observed in any of 
the patients during the halofantrine treatment. 
Preexisting immunity is one of the major deter-
minants of the therapeutic efficacy of antimalar-
ials. Thus, efficacy in nonimmune patients cannot 
be deduced from efficacy in the semi-immune [7]. 
This explains, for example, the higher recrudes-
cence rate in infants, who by definition are consid-
ered non-immune. 
To evaluate the efficacy of halo fan trine in non-
immune individuals we performed a prospective 
c1inical trial in five German institutions specializ-
ing in tropical diseases. Inc1uded were nonimmune 
travelers who developed acute malaria after return-
ing from endemic areas with a parasite count of 
up to 5%. Two different treatments were com-
pared: patients of group A received 3 x 500 mg ha-
lofantrine at 6-h intervals on the day of study entry 
and patients of group B received a second treat-
ment, with the same dosage, 7 days later. We in-
c1uded 80 patients with imported P. jalciparum or 
p, vivax malaria. In more than half of these pa-
tients malaria occurred despite prophylaxis with 
chloroquine, proguanil, or mefloquine. Halofan-
trine c1eared parasitemia in all 80 patients. The 
c1earance time was 53 hand parasite c1earance time 
65 h. However, recrudescense occurred in 3 of 27 
patients in group A (11 %) whereas in group B 
none of the 53 patients developed further episodes 
of parasitemia [11]. Similar observations were 
made in a Swiss study with a similar protocol [4] 
as wen as in two French trials [2, 19]. 
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Thus, in nonimmune patients, in whom the ma-
jority of imported malaria eases oceur in Europe, 
a secondary treatment course with 3 x 500 mg ha-
lofantrine on day 7 is indicated in addition to the 
primary therapy on day 1. 
Stand-by therapy 
The worldwide inerease in antimalarial drug resis-
tance represents a major problem for the inereasing 
tourism to endemie areas. The malaria incidence 
in nonimmune travelers to endemie areas - for in-
stance in more than 2 million Germans in 1988 
[30] - is higher than expeeted. When traveling to 
West Afriea, the incidence without ehemoprophy-
laxis is as high as 2.4 cases of clinieal disease per 
100 travelers per month. A survey of more than 
11000 travelers to endemie areas indicated that, 
although most of the travelers were informed 
about the risk of malaria at their destination, only 
55% carried out eorrect and eonsequent malaria 
ehemoprophylaxis, and less than 5% 90rrect and 
eonsequent exposure prophylaxis [23]. 
The World Health Organization explicity states 
that even with correctly performed ehemoprophy-
laxis, complete proteetion against malaria is not 
guaranteed [29]. This is especially true for stays 
in areas with multiple resistanee and high transmis-
sion rate. In a reeent study by the Centers for Dis-
ease Control the monthly incidenee of P. jalcipar-
um infeetion des pi te correct ehloroquine prophy-
laxis aeeounted for 2.7 eases per 100 per month 
in peace corps volunteers in West Afriea. Despite 
consequent mefloquine prophylaxis at biweekly in-
tervals 1/100 nonimmune persons developed acute 
malaria [10]. In addition, all antimalarials used for 
ehemoprophylaxis are known to induce adverse 
events in up to 7-45% of travelers, whieh eonse-
quently leads to poor eomplianee and less pro tec-
tion [22]. 
Thus, the World Health Organization recom-
mends for the malaria areas Band C that persons 
take along a eurative dose of an antimalarial [29]. 
The major element of this stand-by eoncept of the 
World Health Organization is that travelers to en-
demie areas earry out a eonsequent exposure pro-
phylaxis, including the use ofimpregnated mosqui-
to nets, mosquite repellants, mosquito eoils, and 
appropriate clothing (long sleeves and trousers) 
[8]. If in spite of these precautionary measures 
symptoms of malaria oecur within 7 days of arriv-
al, and a physieian is not immediately available, 
travelers should take one curative dose of the 
stand-by drug as self-medication to avoid delaying 
the start of treatment. In every case, however, a 
physician must be consulted as soon as possible 
for eonfirmation of diagnosis and for possible fur-
ther treatment. The antimalarial used as stand-by 
drug must be effective against all forms of malaria, 
have a low failure rate and a short fever and para-
site clearance time, and above all be weIl tolerated. 
This is espeeially important with regard to possible 
misdiagnosis, as patients may not eome to harm 
by the self-medication. As halofantrine fuHills 
these requirements, the Working Group on malaria 
prophylaxis and therapy of the German Society 
for Tropical Medicine reeommends and the Bun-
desgesundheitsamt (Feder al Health Authority) ap-
proves halofantrine as first drug for stand-by treat-
ment of aeute malaria [8]. 
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